What are the pre‑operative recommendations for discontinuing low‑dose aspirin in a patient with three‑vessel coronary artery disease undergoing elective surgery?

Pre-operative Aspirin Management in 3-Vessel CAD

In patients with three-vessel coronary artery disease undergoing elective noncardiac surgery, aspirin should generally be continued perioperatively (75-100 mg daily) unless the patient has a recent coronary stent or the surgery involves a closed space where bleeding risk is prohibitive. 1

Key Decision Points

For Patients WITHOUT Prior PCI/Stenting

Continue aspirin through the perioperative period when cardiac risk outweighs bleeding risk – this is the recommended approach for most patients with established CAD including 3-vessel disease. 1 The 2024 ACC/AHA guidelines provide a Class IIb recommendation (may be reasonable) for continuing aspirin in CAD patients without prior stenting when cardiac event risk exceeds surgical bleeding risk. 1

Important caveat: The evidence supporting perioperative aspirin continuation in non-stented CAD patients is actually mixed. The POISE-2 trial (10,010 patients) showed that aspirin neither reduced death/MI (7.0% vs 7.1%, p=0.92) nor increased major bleeding significantly in the overall population, though bleeding was numerically higher. 2 However, guidelines still favor continuation based on the high thrombotic risk in 3-vessel CAD patients. 1

For Patients WITH Prior PCI/Stenting

The timing since stent placement fundamentally changes management:

If stented >12 months ago (for ACS indication) or >6 months ago (for stable CAD): Continue aspirin 75-100 mg perioperatively. 1 Recent data from the ASSURE-DES trial (2024) showed no significant difference in ischemic outcomes between continuing aspirin vs holding all antiplatelets in stable patients >1 year post-DES (0.6% vs 0.9% event rate, p>0.99), though minor bleeding was higher with aspirin (14.9% vs 10.1%). 3

If stented <6 months ago: Surgery should ideally be delayed, and if it cannot be delayed, dual antiplatelet therapy (DAPT) should be continued unless bleeding risk is prohibitive. 1

If stented <30 days ago: Elective surgery is contraindicated (Class III: Harm) due to extremely high stent thrombosis risk. 1

Surgical Bleeding Risk Considerations

High-bleeding-risk procedures (intracranial, spinal canal, posterior chamber of eye, prostate surgery): Even in 3-vessel CAD, the bleeding consequences may outweigh thrombotic benefits, requiring individualized multidisciplinary discussion. 1

Standard surgical procedures: Continue aspirin in most cases given the established CAD. 1

Common Pitfalls to Avoid

• Do not stop aspirin abruptly without surgical consultation – aspirin withdrawal can precipitate acute coronary events in high-risk CAD patients 4

• Do not confuse primary prevention with secondary prevention – these guidelines apply to established 3-vessel CAD (secondary prevention), where aspirin benefits are clear, unlike primary prevention where recent data show minimal benefit 5

• Do not assume all CAD patients need the same approach – recent stent placement dramatically changes the risk-benefit calculation 1

Practical Algorithm

1. Determine stent status: Has the patient had PCI?

   • No prior PCI: Continue aspirin 75-100 mg unless closed-space surgery 1
   • Prior PCI: Proceed to step 2

2. If prior PCI, determine timing:

   • >12 months (ACS) or >6 months (stable CAD): Continue aspirin 1
   • 3-6 months: Continue aspirin; consider continuing P2Y12 inhibitor based on bleeding risk 1
   • <3 months: Delay surgery if possible; if urgent, continue DAPT 1
   • <30 days: Do not perform elective surgery 1

3. Assess surgical bleeding risk: If closed-space surgery, multidisciplinary discussion required regardless of above 1

4. Resume aspirin immediately postoperatively if held, ideally within 24-48 hours 1

Conflicting Evidence Note

While older 2014 guidelines were more conservative about aspirin continuation in non-stented patients (Class IIb, "may be reasonable"), 1 the 2024 guidelines maintain this cautious stance but emphasize continuation in prior PCI patients more strongly (Class I recommendation). 1 The POISE-2 and ASSURE-DES trials suggest aspirin's perioperative benefits may be smaller than historically believed, but the catastrophic consequences of stent thrombosis justify continuation in stented patients. 2, 3